Caris Life Sciences (CAI) Share-based Compensation (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Share-based Compensation of $56000.0 for Q1 2026, down 99.62% year-over-year from $14.7 million in Q1 2025, and up 100.11% quarter-over-quarter from -$52.8 million in Q4 2025.
Caris Life Sciences (CAI) Share-based Compensation (2024 - 2026) Analysis & Trends
Caris Life Sciences' Share-based Compensation history runs 3 years deep, the most recent figure standing at $56000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation fell 99.62% year-over-year to $56000.0; the TTM figure through Mar 2026 stood at -$10.8 million (changed N/A YoY), while the FY2025 annual figure was $3.9 million, up 431.17% from the prior year.
- Share-based Compensation for Q1 2026 stood at $56000.0, up from -$52.8 million in the prior quarter.
- The five-year high for Share-based Compensation was $55.0 million in Q3 2025, with the low at -$52.8 million in Q4 2025.
- The 3-year median for Share-based Compensation is $56000.0 (2026), against an average of -$615857.1.
- Peak annual rise in Share-based Compensation reached 714.79% in 2025, while the deepest fall reached 7381.1% in 2025.
- Caris Life Sciences' Share-based Compensation stood at $725000.0 in 2024, then tumbled by 7381.1% to -$52.8 million in 2025, then soared by 100.11% to $56000.0 in 2026.
- Business Quant data shows CAI's Share-based Compensation at $56000.0 in Q1 2026, -$52.8 million in Q4 2025, and $55.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn | 22.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.22 Mn |
| Jun 30, 2026 | 22.22 Mn |
| Mar 31, 2026 | 56,000.00 |
| Mar 31, 2026 | 56,000.00 |
| Dec 31, 2025 | -52.79 Mn |
| Dec 31, 2025 | -52.79 Mn |
| Sep 30, 2025 | 54.98 Mn |
| Sep 30, 2025 | 54.98 Mn |
| Jun 30, 2025 | -13.03 Mn |
| Jun 30, 2025 | -13.03 Mn |
| Mar 31, 2025 | 14.69 Mn |
| Mar 31, 2025 | 14.69 Mn |
| Dec 31, 2024 | 725,000.00 |
| Dec 31, 2024 | 725,000.00 |
| Sep 30, 2024 | -8.94 Mn |
| Sep 30, 2024 | -8.94 Mn |